Yongxin Liang

Ms. Yongxin Liang

Erasmus MC
+1
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2021 in Cancers
Verified
Journal Article
Open access
PDF file
ESEnzo Scutigliani
Enzo Scutigliani
Yongxin LiangYongxin Liang
Yongxin Liang
Johannes Hans CrezeeJohannes Hans Crezee
Johannes Hans Crezee
RKRoland Kanaar
Roland Kanaar
PKPrzemek Krawczyk
Przemek Krawczyk
Cancer treatments based on mild hyperthermia (39–43 °C, HT) are applied to a widening range of cancer types, but several factors limit their efficacy and slow down more widespread adoption. These factors include difficulties in adequate heat delivery, a short therapeutic window and the acquisition of thermotolerance by cancer cells. Here, we explore the biological effects of HT, the cellular responses to these effects and their clinically-relevant consequences. We then identify the heat stress response—the cellular defense mechanism that detects and counteracts the effects of heat—as one of the major forces limiting the efficacy of HT-based therapies and propose targeting this mechanism as a potentially universal strategy for improving their efficacy.

26 October 2022 in Cancers
Verified
Journal Article
Open access
PDF file
ESEnzo Scutigliani
Enzo Scutigliani
Yongxin LiangYongxin Liang
Yongxin Liang
MIMarloes IJff
Marloes IJff
HRHans Rodermond
Hans Rodermond
XMXionge Mei
Xionge Mei
PKPrzemek Krawczyk
Przemek Krawczyk
Hyperthermia is being used as a radio- and chemotherapy sensitizer for a growing range of tumor subtypes in the clinic. Its potential is limited, however, by the ability of cancer cells to activate a protective mechanism known as the heat stress response (HSR). The HSR is marked by the rapid overexpression of molecular chaperones, and recent advances in drug development make their inhibition an attractive option to improve the efficacy of hyperthermia-based therapies. Our previous in vitro work showed that a single, short co-treatment with a HSR (HSP90) inhibitor ganetespib prolongs and potentiates the effects of hyperthermia on DNA repair, enhances hyperthermic sensitization to radio- and chemotherapeutic agents, and reduces thermotolerance. In the current study, we first validated these results using an extended panel of cell lines and more robust methodology. Next, we examined the effects of hyperthermia and ganetespib on global proteome changes. Finally, we evaluated the potential of ganetespib to boost the efficacy of thermo-chemotherapy and thermo-radiotherapy in a xenograft murine model of cervix cancer. Our results revealed new insights into the effects of HSR inhibition on cellular responses to heat and show that ganetespib could be employed to increase the efficacy of hyperthermia when combined with radiation.